DelveInsight’s "Chronic Obstructive Pulmonary Disease (COPD)- Epidemiology Forecast–2032" report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Chronic Obstructive Pulmonary Disease (COPD) Disease Understanding
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
In the United States, the term COPD includes two main conditions—emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy. This damage also can destroy the walls of the air sacs, leading to fewer and larger air sacs instead of many tiny ones. If this happens, the amount of gas exchange in the lungs is reduced.
The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging.
Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients. These symptoms may vary from day to day and may precede the development of airflow limitation by many years.
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis
COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Spirometry is required to diagnose in this clinical context; the presence of a post-bronchodilator FEV1/FVC <0.70 confirms the presence of persistent airflow limitation and, thus, COPD in patients with appropriate symptoms and significant exposures to noxious stimuli. The spirometric criterion for airflow limitation remains a post-bronchodilator fixed ratio of FEV1/FVC < 0.70. This criterion is simple and independent of reference values and has been used in numerous clinical trials that form the evidence base from which most treatment recommendations are drawn. It should be noted that the use of the fixed FEV1/FVC ratio to define airflow limitation may result in the more frequent diagnosis of COPD in the elderly and less frequent diagnosis in adults <45 years, especially in mild disease, compared to using a cut-off based on the lower limit of normal (LLN) values for FEV1/FVC.
Continued in the report…..
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of COPD, gender-specific diagnosed prevalent cases of COPD, age-specific diagnosed prevalent cases of COPD, diagnosed prevalent cases of COPD based on severity of airflow limitation, and diagnosed prevalent cases of COPD based on symptoms and exacerbation history in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Chronic Obstructive Pulmonary Disease (COPD) Detailed Epidemiology Segmentation
• The diagnosed prevalent cases of COPD in the 7MM was 34,640,030 in 2020. These cases are expected to increase throughout the forecast period, i.e., 2021–2032.
• The estimates suggest higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020 which is expected to increase during the forecast period (2021–2032).
• In 2020, a lower number of males were affected by this disease contributing 6,588,516 total diagnosed prevalent population of COPD in the United States. In comparison, there were 10,867,088 females affected by COPD in 2020, in the US.
• In the epidemiology model of COPD, there are multiple age groups referred ranging from 18–44 years, 45–54 years, 55–64 years, 64–74 years, and 75+ years, for COPD. In the US, the highest cases were reported in the age group of 55–64 years i.e. 4,601,558 in 2020.
• The majority of cases of COPD are female in the US. But in EU-5 and Japan the diagnosed cases of COPD in males represents majority of the cases. Overall, in the 7MM, females are predominantly high in number.
• In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4 criteria, respectively based on severity of airflow limitation.
• Among total diagnosed prevalent cases of COPD in the US, 53% were acquired by GOLD A based on symptoms and exacerbation history. Rest of the cases were occupied by other types as 27% by GOLD B, 8% by GOLD C and 12% by GOLD D.
• Among the five major European countries, Italy has the highest diagnosed prevalent population followed by France and Germany. On the other hand, the United Kingdom had the lowest diagnosed prevalent population.
Scope of the Report
• The report covers the descriptive overview of COPD, explaining its signs and symptoms, causes, classification, and diagnosis.
• Comprehensive insight has been provided into COPD epidemiology.
• The report provides insight into the 7MM historical and forecasted patient population covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Chronic Obstructive Pulmonary Disease (COPD).
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, total diagnosed prevalent cases of COPD, gender-specific diagnosed prevalent cases of COPD, age-specific diagnosed prevalent cases of COPD, diagnosed prevalent cases of COPD based on severity of airflow limitation, and diagnosed prevalent cases of COPD based on symptoms and exacerbation history.
Report Highlights
• 10-Year Forecast of COPD
• 7MM Coverage
• Total Diagnosed Prevalent Cases of COPD
• Gender-specific Diagnosed Prevalent Cases of COPD
• Age-specific Diagnosed Prevalent Cases of COPD
• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation
• Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History
Key Questions Answered
• What is the unmet needs of COPD?
• What is the historical COPD patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of COPD at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to COPD?
• Out of the above-mentioned countries, which country would have the highest prevalent population of COPD during the forecast period (2021–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2032)?
Reasons to buy
The Chronic Obstructive Pulmonary Disease (COPD) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Chronic Obstructive Pulmonary Disease (COPD) epidemiology forecast.
• The Chronic Obstructive Pulmonary Disease (COPD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Chronic Obstructive Pulmonary Disease (COPD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032
- 1 Key Insights
- 2 Report Introduction
- 3 Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance
- 3.1 Market Share (%) Distribution of COPD by Class in 2019
- 3.2 Market Share (%) Distribution of COPD by Class in 2032
- 4 Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)
- 5 Key Events
- 6 Disease Background and Overview
- 6.1 Introduction
- 6.2 Factors That Influence Disease Development and Progression
- 6.3 Symptoms
- 6.4 Types
- 6.5 Classification
- 6.6 Stages
- 6.7 Pathology, Pathogenesis, and Pathophysiology
- 6.8 Diagnosis
- 6.8.1 Differential Diagnosis
- 6.8.2 Diagnostic Algorithm
- 6.8.3 Diagnostic Guidelines
- 6.8.3.1 Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
- 6.8.3.2 Chronic Obstructive Pulmonary Disease: Diagnosis and Management
- 6.8.3.3 Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition
- 6.9 Treatment and Management
- 6.1 Treatment Algorithm Chronic obstructive pulmonary disease (COPD)
- 6.11 Guidelines
- 6.11.1 Chronic Obstructive Pulmonary Disease in over 16s: Nonpharmacological Management and Use of Inhaled Therapies: NICE
- 6.11.2 Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline 2020
- 6.11.3 Global Initiative for Chronic Obstructive Lung Disease Guideline 2021
- 6.12 Vaccination in COPD
- 6.12.1 Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition: The Japanese Respiratory Society
- 6.12.2 Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline: Kaiser Foundation Health Plan of Washington
- 7 Epidemiology and Patient Population
- 7.1 Key Findings
- 7.2 Methodology of Epidemiology
- 7.3 Assumptions and Rationale: 7MM
- 7.3.1 US Assumptions and Rationale
- 7.3.2 EU5 Assumptions and Rationale
- 7.3.3 JP Assumptions and Rationale
- 7.4 Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM
- 7.5 The United States
- 7.5.1 Diagnosed Prevalent Cases of COPD in the United States
- 7.5.2 Gender-specific Diagnosed Prevalent Cases of COPD in the United States
- 7.5.3 Age-specific Diagnosed Prevalent Cases of COPD in the United States
- 7.5.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States
- 7.5.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States
- 7.6 Europe
- 7.6.1 Diagnosed Prevalent Cases of COPD in Europe
- 7.6.2 Gender-specific Diagnosed Prevalent Cases of COPD in Europe
- 7.6.3 Age-specific Diagnosed Prevalent Cases of COPD in Europe
- 7.6.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe
- 7.6.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe
- 7.7 Japan
- 7.7.1 Diagnosed Prevalent Cases of COPD in Japan
- 7.7.2 Gender-specific Diagnosed Prevalent Cases of COPD in Japan
- 7.7.3 Age-specific Diagnosed Prevalent Cases of COPD in Japan
- 7.7.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan
- 7.7.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan
- 8 Patient Journey
- 9 Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)
- 10 KOL Views
- 11 Market Drivers
- 12 Market Barriers
- 13 SWOT Analysis
- 14 Unmet Needs
- 15 Reimbursement and Market Access
- 15.1 United States
- 15.2 Europe
- 15.3 Japan
- 16 Appendix
- 16.1 Bibliography
- 16.2 Report Methodology
- 17 DelveInsight Capabilities
- 18 Disclaimer
- 19 About DelveInsight
- Table 1: Summary of COPD Market and Epidemiology (2019–2032)
- Table 2: Key Events
- Table 3: COPD Classification According to Symptom and Severity Risk
- Table 4: Key Indicators for Considering a Diagnosis for COPD
- Table 5: Classification of Airflow Limitation Severity in COPD (Based on Post-bronchodilator FEV1)
- Table 6: Differential Diagnosis of COPD
- Table 7: Pharmacological Characteristics of Approved Bronchodilators for COPD Treatment
- Table 8: Pharmacological Treatment of COPD Based on Phenotypes and Disease Severity (GOLD stage I–IV)
- Table 9: Antibiotic Dosing for Treatment of COPD Exacerbations
- Table 10: Pharmacologic Options That are not Recommended for COPD
- Table 11: Key points
- Table 12: Vaccination For Stable COPD
- Table 13: Total Diagnosed Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM, in 000’s (2019–2032)
- Table 14: Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Table 15: Gender-specific Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Table 16: Age-specific Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Table 17: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States, in 000’s (2019–2032)
- Table 18: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States, in 000’s (2019–2032)
- Table 19: Diagnosed Prevalent Cases of COPD in Europe, in 000’s (2019–2032)
- Table 20: Gender-specific Diagnosed Prevalent Cases of COPD in Europe, in 000’s (2019–2032)
- Table 21: Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease in Europe, in 000’s (2019–2032)
- Table 22: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe, in 000’s (2019–2032)
- Table 23: COPD Classification Based on Symptoms and Exacerbation History in Europe, in 000’s (2019–2032)
- Table 24: Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Table 25: Gender-specific Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Table 26: Age-specific Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Table 27: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan, in 000’s (2019–2032)
- Table 28: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan, in 000’s (2019–2032)
- Table 29: Organizations contributing toward COPDFigure 1: Etiology, Pathobiology, Pathology of COPD Leading to Airflow Limitation and Clinical Manifestations
- Figure 2: Types of COPD – Emphysema and Chronic Bronchitis
- Figure 3: Pathways of the Diagnosis of COPD
- Figure 4: Spirometry Tracing in Normal Individual Versus Spirometry Tracing Typical of a Patient With Obstructive Disease
- Figure 5: ABCD Assessment Tool
- Figure 6: Diagnostic Algorithm of the Clinical Phenotypes
- Figure 7: Flowchart for the Treatment of Stable Chronic Obstructive Pulmonary Disease (COPD)
- Figure 8: Bronchodilator Therapy for Patients With Confirmed, Stable COPD
- Figure 9: Algorithm for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Figure 10: Follow-up Pharmacological Treatment
- Figure 11: Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM, in 000’s (2019–2032)
- Figure 12: Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Figure 13: Gender-specific Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Figure 14: Age-specific Diagnosed Prevalent Cases of COPD in the United States, in 000’s (2019–2032)
- Figure 15: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States, in 000’s (2019–2032)
- Figure 16: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States, in 000’s (2019–2032)
- Figure 17: Diagnosed Prevalent Cases of COPD in Europe, in 000’s (2019–2032)
- Figure 18: Gender-specific Diagnosed Prevalent Cases of COPD in Europe, in 000’s (2019–2032)
- Figure 19: Age-specific Diagnosed Prevalent Cases of COPD in Europe, in 000’s (2019–2032)
- Figure 20: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe, in 000’s (2019–2032)
- Figure 21: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe, in 000’s (2019–2032)
- Figure 22: Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Figure 23: Gender-specific Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Figure 24: Age-specific Diagnosed Prevalent Cases of COPD in Japan, in 000’s (2019–2032)
- Figure 25: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan, in 000’s (2019–2032)
- Figure 26: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan, in 000’s (2019–2032)
- Figure 27: Patient Journey
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook